Resident: Attending: Expert: User: Stage 1: History & Presentation (Timestamp: 1 Year Prior to Admission)
A 53-year-old male sales executive (residing in Delhi NCR, non-smoker, non-drinker) presents to the neuro-endocrinology clinic with a 1-year history of progressive nasal congestion, severe evening headaches, double vision (diplopia), polydipsia, and polyuria.
HPI:
- 1 Year Ago: Developed nasal congestion and headaches. Sinus MRI showed diffuse right sphenoid mucosal thickening with inspissated secretions; underwent endoscopic sinus antrostomy without improvement.
- 7.5 Months Ago: Developed worsening binocular horizontal diplopia on lateral gaze. Neuro-ophthalmology exam revealed bilateral abduction deficits (right > left sixth nerve palsy / esotropia). Pituitary MRI showed pituitary enlargement (17 mm) and sphenoid sinus inflammation. Received 3 weeks of oral steroids with temporary resolution of diplopia.
- 4.5 Months Ago: Developed severe thirst (polydipsia) and voluminous polyuria (up to 6 L/day of clear urine). Water deprivation test confirmed Central Diabetes Insipidus (undetectable ADH, 150% rise in urine osmolality after DDAVP). Started on intranasal desmopressin twice daily.
Hello, Chief Resident here.
Key Findings:
A 53-year-old male presenting with refractoriness to sinus surgery, steroid-responsive bilateral sixth nerve palsy, pituitary mass (17 mm), and Central Diabetes Insipidus, centered around sphenoid-parasellar inflammation.
Differential Diagnoses:
1. IgG4-Related Disease / Hypophysitis (35%): Accounts for contiguous sphenoid sinusitis, steroid-responsive pituitary/dural enlargement, CN VI palsies, and CDI.
2. Granulomatosis with Polyangiitis (GPA) (30%): Characterized by chronic sinus involvement unresponsive to antrostomy, skull base extension, CN palsies, and infundibular CDI.
3. Neurosarcoidosis (20%): Basal pachymeningitis and granulomatous infiltration frequently target the hypothalamic-pituitary axis (CDI) and cranial nerves.
4. Chronic Invasive Fungal Sinusitis (e.g., Aspergillus) (15%): Indolent sphenoid sinus infection extending into the parasellar space; temporary steroid response reflects reduced perilesional edema.
Recommended Prioritized Tests:
1. Serum IgG4 levels and ANCA Panel (PR3 and MPO).
2. Serum Angiotensin-Converting Enzyme (ACE) and serum/urine calcium.
3. Repeat Pituitary/Skull Base MRI with dynamic gadolinium enhancement.
4. CSF Analysis: Cell count, protein, glucose, ACE, cytology, and fungal cultures/PCR.
5. Endoscopic Sphenoid/Parasellar Tissue Biopsy: Histopathology with special stains (IgG4/IgG ratio, GMS, tissue ANCA/granulomas).
Hello Attending Consultant here
Critique: Solid prioritization of biopsy and serologies, but underweights systemic staging and infectious mimics; steroids already given risk masking histology—delay further empiric Rx. CSF before biopsy is low-yield without meningeal signs; add chest imaging early.
Top 3 DDx:
1. IgG4-related hypophysitis/pachymeningitis
2. GPA (ANCA vasculitis)
3. Neurosarcoidosis
Specific points (6):
1. Order serum IgG4 + subclass ratios + ANCA (PR3/MPO) STAT.
2. Add QuantiFERON, β-D-glucan, galactomannan, and serum ACE/Ca.
3. CT chest/abdomen for sarcoid/GPA nodules or IgG4 adenopathy.
4. Repeat MRI with CISS/FIESTA sequences for CN VI cisternal detail + dural tail.
5. Proceed to endoscopic biopsy (sphenoid + pituitary stalk if feasible) with IgG4 IHC, GMS, AFB, and flow cytometry.
6. Hold further steroids; initiate DDAVP titration and baseline pituitary panel (AM cortisol, IGF-1, TFT, gonadotropins).
7. Ophthalmology follow-up for prism/serial Hess charting.
Hello, Expert Clinician here.
Best Unifying Diagnosis: IgG4-related disease with hypophysitis and skull-base pachymeningitis — unifies the steroid-responsive bilateral CN VI palsy, pituitary enlargement with stalk-mediated CDI, and refractory sphenoid disease under one fibroinflammatory process.
Top Differentials:
- GPA: Sinusitis + CDI + cranial neuropathy fit, but absence of pulmonary/renal involvement or bony erosion argues against; ANCA decisive.
- Neurosarcoidosis: CDI classic and dural predilection fits, yet isolated sphenoid disease is atypical; chest CT/ACE needed.
- Chronic invasive fungal sinusitis (Aspergillus): Endemic to North India; inspissated secretions fit. Steroid "response" may merely reduce perilesional edema while infection smolders — must exclude before immunosuppression.
- Lymphoma/histiocytosis (ECD/LCH): CDI is a hallmark; only tissue separates these.
Key Pivot: Anatomic convergence of sphenoid, cavernous sinus, and infundibulum signals a single infiltrative skull-base process, and CDI essentially excludes simple adenoma.
Next Move: Endoscopic biopsy of sphenoid/stalk tissue with IgG4 immunostaining, fungal stains/cultures, and lymphoma markers — obtained before further steroids, which obscure histology.
Teaching Pearl: Diabetes insipidus virtually never accompanies pituitary adenoma; CDI plus a pituitary mass mandates a search for infiltrative, inflammatory, or metastatic stalk disease.
Stage 2: Physical & Neurological Examination (Timestamp: Admission / Day 1)
Physical Exam: T 36.8°C (afebrile), HR 72 bpm, BP 124/76 mmHg, RR 14/min, SpO2 99% room air.
Neurological & ENT Exam: Fully oriented, cranial nerves I-XII intact (diplopia resolved). No proptosis, facial numbness, or ocular inflammation. Nasal endoscopy normal without mucopurulent discharge or mucosal erosions.
Initial Laboratory Evaluation:
- Hemogram & Chemistry: Hb 13.7 g/dL, WBC 6.8 x 10³/µL, Platelets 240,000/µL. Normal electrolytes, liver, and renal function. Normal ESR (23 mm/hr).
- Endocrine Panel: Central Diabetes Insipidus controlled on DDAVP. Borderline low testosterone (229 ng/dL), normal TSH, Free T4 (0.8 ng/dL), morning Cortisol (7.9 µg/dL with normal cosyntropin stimulation peak 21.7 µg/dL), Prolactin (12.1 ng/mL), and IGF-1 (330 ng/mL).
- Autoimmune & Serologic Panel: Weakly positive MPO-ANCA (9 U/mL; ref <2.8 U/mL), PR3-ANCA negative, Serum IgG4 concentration normal (and normal SPEP).
Hello, Chief Resident here.
Updated Key Findings:
53-year-old male with resolved CN VI palsy, controlled CDI, mild hypogonadism, normal serum IgG4, and a weakly positive MPO-ANCA (9 U/mL) following refractory sphenoid inflammation and pituitary mass.
Differential Diagnoses:
1. Granulomatosis with Polyangiitis (GPA) / ANCA Vasculitis (45%): Positive MPO-ANCA combined with refractory sphenoiditis, infundibular involvement (CDI), and transient CN VI palsy strongly points to localized skull-base GPA.
2. IgG4-Related Disease / Hypophysitis (25%): Serum IgG4 levels are normal in up to 40% of histopathologically proven cases; clinical phenotype remains highly compatible.
3. Neurosarcoidosis (15%): Basal infiltrative process targeting the pituitary stalk and cranial nerves, though MPO-ANCA positivity is atypical.
4. Chronic Invasive Fungal Sinusitis (15%): Indolent fungal infection (e.g., Aspergillus) with secondary pachymeningitis; must be definitively excluded prior to immunosuppression.
Recommended Prioritized Next Steps:
1. Endoscopic Surgical Biopsy (sphenoid mucosa/dura/stalk) for histology, IgG4/IgG immunohistochemistry, and fungal/bacterial/AFB cultures.
2. Contrast CT Chest/Abdomen/Pelvis to evaluate for subclinical pulmonary nodules, renal involvement, or lymphadenopathy.
3. High-Resolution Pituitary/Skull Base MRI to re-assess mass extent and dural enhancement.
Hello Attending Consultant here
Critique: Over-weights weak MPO-ANCA (low-titer, non-specific without PR3 or systemic features); under-emphasizes need to exclude infection/malignancy pre-immunosuppression. Normal IgG4 and ESR do not exclude IgG4-RD or sarcoid. Biopsy remains pivotal—delay imaging staging only if unstable.
Top 3 DDx:
1. Localized GPA (MPO-ANCA+ skull-base)
2. IgG4-related hypophysitis/pachymeningitis
3. Chronic invasive fungal sinusitis
Specific points (6):
1. Repeat ANCA ELISA + IIF; add anti-GBM if renal hint emerges.
2. CT chest (HRCT) first for occult nodules/cavities before full CAP.
3. Urgent endoscopic sphenoid biopsy: H&E, IgG4/IgG ratio, GMS/AFB, cultures, next-gen sequencing.
4. MRI brain/orbits with contrast + DWI to map residual stalk/cavernous enhancement.
5. Quantiferon, serum/urine protein electrophoresis, β2-microglobulin.
6. Hold steroids/rituximab; monitor DDAVP and serial testosterone/cortisol.
7. ENT/rheum co-management for potential cyclophosphamide if GPA confirmed.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Localized skull-base IgG4-related hypophysitis/pachymeningitis remains most unifying — sphenoid disease, steroid-responsive CN VI palsies, and CDI cohere. Crucially, normal serum IgG4 does not exclude it; up to 30–40% of biopsy-proven cases are seronegative, and normal ESR fits its fibroinflammatory, smoldering phenotype.
Top Differentials:
- GPA: Weak MPO-ANCA (9 U/mL) is a red herring until proven otherwise — low-titer MPO positivity is nonspecific, PR3 negative, and ESR normal with zero systemic features. Tissue ANCA does not exist; biopsy decides.
- Chronic invasive fungal sinusitis: Still the dangerous must-exclude; prior steroids could unmask it.
- Lymphoma/histiocytosis: CDI + pituitary mass is a classic LCH/lymphoma presentation; normal blood counts mean nothing.
Key Pivot: All serologies are now either normal or weakly equivocal — this is a tissue diagnosis case. Serologic ambiguity must not delay biopsy or tempt empiric immunosuppression.
Next Move: Endoscopic sphenoid/dural biopsy with IgG4 IHC, fungal stains/cultures, and flow cytometry — urgently, steroid-free.
Teaching Pearl: A low-titer MPO-ANCA without systemic disease has poor positive predictive value; in skull-base inflammation, biopsy trumps serology every time.
Stage 3: Pituitary & Sinus MRI Imaging & CSF Diagnostics (Timestamp: Hospital Days 1-3)
Diagnostic Workup:
- Pituitary & Brain MRI (with Gadolinium):
- Diffuse enlargement of the pituitary gland (19 mm transverse x 11 mm craniocaudal x 13 mm AP) with homogeneous contrast enhancement and abnormal superior convexity.
- Mild thickening and enhancement of the infundibular stalk.
- Extensive mucosal thickening and T2-hypointense soft-tissue tissue filling the right sphenoid sinus with adjacent sphenoid bone sclerosis on facial CT.
- Lumbar Puncture / CSF Analysis: Mild lymphocytic pleocytosis (4 WBCs/µL, 97% lymphocytes), elevated CSF protein (66 mg/dL), normal CSF glucose. CSF ACE, AFP, and beta-hCG all negative.
Hello, Chief Resident here.
Updated Key Findings:
Sphenoid sinus soft tissue with characteristic T2 hypointensity and sphenoid bone sclerosis, contiguous pituitary enlargement (19 mm) with stalk thickening, CSF protein elevation (66 mg/dL), controlled CDI, and weak MPO-ANCA.
Differential Diagnoses:
1. IgG4-Related Disease / Hypophysitis (40%): T2 hypointensity reflecting dense fibrosis, combined with contiguous sphenoid-pituitary infiltration, is highly characteristic. Normal serum IgG4 occurs in ~40% of cases.
2. Chronic Invasive Fungal Sinusitis (30%): T2 hypointensity (macromolecules/fungal elements) and sphenoid bone sclerosis in a North Indian patient strongly suggest indolent fungal infection (Aspergillus).
3. Granulomatosis with Polyangiitis (GPA) (20%): Chronic sphenoiditis with adjacent bone sclerosis, infundibular involvement, and MPO-ANCA positivity remain compatible.
4. Neurosarcoidosis (10%): Stalk thickening and CSF lymphocytic pleocytosis fit, though negative CSF ACE reduces probability.
Recommended Prioritized Next Steps:
1. Urgent Endoscopic Transsphenoidal Biopsy: Evaluate sphenoid mucosa/dura for storiform fibrosis, IgG4/IgG IHC (>10 IgG4+ plasma cells/HPF), and granulomas.
2. Fungal Tissue Workup: Special stains (GMS/PAS), fungal PCR/cultures, and serum galactomannan/β-D-glucan.
3. High-Resolution CT (HRCT) Chest: Screen for occult pulmonary granulomas or nodules.
4. Tissue Flow Cytometry: Formally exclude lymphoma or histiocytosis.
Hello Attending Consultant here
Critique: Over-relies on T2-hypointensity as pathognomonic for IgG4 (also classic for fungus/GPA fibrosis); underplays need for immediate tissue before any Rx. CSF is non-specific—skip further CSF markers. Chest imaging essential but biopsy first.
Top 3 DDx:
1. Chronic invasive fungal sinusitis (Aspergillus)
2. IgG4-related hypophysitis/pachymeningitis
3. Localized GPA (MPO+)
Specific points (6):
1. Urgent endoscopic sphenoid biopsy + frozen section: GMS/PAS, cultures, PCR, IgG4/IgG ratio, AFB.
2. Serum galactomannan, β-D-glucan, Aspergillus IgE/IgG pre-biopsy.
3. HRCT chest for nodules/cavities/infiltrates same day.
4. MRI add DWI/ADC to assess cellularity vs fibrosis.
5. Hold all immunosuppression; continue DDAVP + full pituitary axis recheck.
6. Rheum/ID/ENT board review post-histology; prepare for possible ampho if fungal.
7. Serial visual fields/CN testing q48h.
Hello, Expert Clinician here.
Best Unifying Diagnosis: IgG4-related disease with hypophysitis and sphenoid pachymeningitis still leads — the fibrotic T2-hypointense sphenoid tissue, bony sclerosis, stalk thickening, and CSF lymphocytic protein elevation are coherent with fibroinflammatory IgG4-RD. Seronegativity in ~40% keeps this at the top.
Top Differentials:
- Chronic invasive fungal sinusitis (Aspergillus): The most dangerous mimic — T2 hypointensity from fungal concretions and bone sclerosis in North India make this near-equally probable. Biopsy must arbitrate.
- GPA: Weak MPO, normal ESR, no systemic features — increasingly unlikely but not excluded.
- Sarcoidosis: Negative CSF ACE and absence of systemic disease sharply downgrade this.
Key Pivot: The T2-hypointense signal cuts both ways — it reflects fibrosis (IgG4) or fungal/mycotic material. Imaging has reached its ceiling; only histopathology with fungal stains separates the two leading contenders before any treatment decision.
Next Move: Endoscopic sphenoid biopsy with frozen section, GMS/PAS, cultures, and IgG4 immunostaining — within 48 hours, pre-steroid.
Teaching Pearl: T2 hypointensity in sinonasal disease is a narrowing tool, not a closing one — it flags fibrosis and fungus with equal fidelity; the biopsy needle breaks the tie.
Stage 4: Transsphenoidal Biopsy & Histopathology (Timestamp: Hospital Days 3-5)
Transsphenoidal Biopsy of Pituitary & Sphenoid Sinus:
- Light Microscopy: Dense lymphoplasmacytic infiltrate in pituitary and sinus mucosa accompanied by prominent storiform (woven-mat) fibrosis in the sphenoid sinus. Absence of necrotizing vasculitis, granulomas, multinucleated giant cells, or tumor cells.
- Immunohistochemistry: Staining demonstrated 14 IgG4-positive plasma cells per high-power field within the sphenoid sinus tissue with storiform fibrosis.
- Pathology Unifying Diagnosis: IgG4-Related Hypophysitis and Sinusitis (IgG4-Related Disease / IgG4-RD).
Hello, Chief Resident here.
Updated Key Findings:
Endoscopic sphenoid/pituitary biopsy confirmed IgG4-Related Hypophysitis and Sinusitis (IgG4-RD) based on dense lymphoplasmacytic infiltrate, characteristic storiform fibrosis, absence of necrosis or fungal elements, and 14 IgG4+ plasma cells/HPF.
Final Diagnostic Summary:
1. IgG4-Related Disease / Hypophysitis (95%): Definitive histopathological diagnosis. Meets international consensus criteria for IgG4-RD (storiform fibrosis + IgG4+ plasma cell burden >10/HPF). Explains refractory sphenoiditis, transient CN VI palsies, pituitary mass, and Central Diabetes Insipidus. The weakly positive MPO-ANCA represents a known false-positive/bystander serology.
2. Granulomatosis with Polyangiitis (GPA) (<3%): Excluded by biopsy (absence of necrotizing vasculitis and granulomas).
3. Chronic Invasive Fungal Sinusitis (<2%): Excluded by negative special stains (GMS/PAS) and cultures.
Recommended Prioritized Next Steps:
1. Initiate High-Dose Systemic Glucocorticoids: Prednisone 0.6–1.0 mg/kg/day (e.g., 40–60 mg daily) with planned taper over 2–3 months.
2. Steroid-Sparing Immunomodulatory Therapy: Early introduction of Rituximab (e.g., 1000 mg IV on Days 1 and 15) or Azathioprine to prevent relapse and enable complete steroid weaning.
3. Endocrine Maintenance: Continue intranasal desmopressin (DDAVP); re-evaluate hypothalamic-pituitary-gonadal/thyroid/adrenal axes post-treatment.
4. Surveillance & Staging: Baseline CT Chest/Abdomen/Pelvis for systemic IgG4-RD involvement; repeat Pituitary/Sinus MRI at 3 months to monitor mass reduction.
Hello Attending Consultant here
Critique: Plan appropriately escalates to steroids + rituximab post-biopsy confirmation, but under-specifies IgG4-RD multi-organ staging and relapse surveillance; MPO-ANCA bystander needs no vasculitis Rx. Endocrine repletion timing and infection prophylaxis lag.
Top 3 DDx:
1. IgG4-related hypophysitis/sinusitis (biopsy-proven)
2. Residual localized GPA (excluded)
3. Occult lymphoma (ruled out)
Specific points (6):
1. Start prednisone 40 mg/day + PCP prophylaxis (TMP-SMX); taper per IgG4-RD consensus.
2. Rituximab 1 g IV d1/d15 as steroid-sparing induction; check CD19 depletion.
3. Full-body PET-CT or CT CAP for subclinical IgG4 involvement (pancreas/retroperitoneum).
4. Serial MRI pituitary/sinus at 4–6 wk + 3 mo; track IgG4 levels if initially elevated.
5. Reassess full pituitary panel (cortisol, TFT, gonadal, IGF-1) at 1 mo; continue DDAVP.
6. Rheum/endo co-follow; hold further ANCA workup.
7. Bone density + glycemic monitoring on steroids.
Hello, Expert Clinician here.
Final Unifying Diagnosis: IgG4-related hypophysitis with sphenoid sinusitis and pachymeningitis — biopsy-secured by storiform fibrosis, lymphoplasmacytic infiltrate, and elevated IgG4+ plasma cells, elegantly unifying the refractory sinusitis, transient CN VI palsies, pituitary mass, and CDI.
Retrospective Fit:
- GPA (excluded): No vasculitis or granulomas on tissue; weak MPO-ANCA was a bystander — validating earlier caution against serologic over-interpretation.
- Fungal sinusitis (excluded): Negative GMS/PAS stains; T2 hypointensity reflected fibrosis, not concretions — confirming the biopsy tie-break was essential.
- Sarcoidosis (excluded): No granulomas; never truly fit.
Key Pivot of the Case: The decision to biopsy before empiric immunosuppression — serology was uniformly misleading (normal IgG4, weak MPO), imaging was equivocal, and only histopathology separated the three dangerous mimics. This is the defining diagnostic discipline of the case.
Next Management Move: Induction glucocorticoids with rituximab as steroid-sparing therapy, plus whole-body staging (PET-CT) for occult systemic IgG4-RD, and serial pituitary axis reassessment.
Teaching Pearl: In IgG4-RD, serum IgG4 can be normal and ANCA weakly positive simultaneously — the diagnosis lives in the tissue: storiform fibrosis is the signature, not the serology.
Stage 5: Targeted B-Cell Depletion Therapy & Complete Recovery (Timestamp: Follow-up & Discharge)
Management & Outcome:
- Induction Therapy: Oral Prednisone 60 mg daily with a 6-month taper paired with B-cell depletion therapy (Rituximab 1 g IV x 2 doses on days 1 and 15).
- Clinical Outcome:
- Complete resolution of diabetes insipidus, allowing total discontinuation of desmopressin.
- Follow-up MRI at 17 months showed complete resolution of pituitary gland enlargement and infundibular stalk thickening.
- Sustained long-term disease-free remission at 4-year follow-up without any recurring symptoms or immunosuppressive medications.
Hello, Chief Resident here.
Updated Key Findings:
A 53-year-old male with biopsy-proven IgG4-Related Hypophysitis and Sinusitis achieved complete radiological resolution (pituitary/stalk normalization at 17 months), full functional recovery of the neurohypophysis (CDI resolved, DDAVP discontinued), and sustained medication-free remission at 4-year follow-up after Rituximab and steroid therapy.
Final Differential Diagnosis:
1. IgG4-Related Hypophysitis and Sinusitis (100%): Histopathologically confirmed and supported by complete clinical, endocrine, and radiological cure following B-cell depletion therapy.
Analysis & Management Plan:
This case highlights the curative potential of targeted B-cell depletion (Rituximab) in IgG4-RD. Achieving complete reversal of Central Diabetes Insipidus—a typically irreversible deficit once infundibular fibrosis sets in—demonstrates the critical importance of early tissue diagnosis and prompt disease-modifying therapy before permanent neuronal damage occurs.
Next Steps & Long-term Care:
1. Long-term Surveillance: Annual clinical, visual, and baseline endocrine evaluations (morning cortisol, thyroid panel) to monitor for late disease recurrence.
2. Symptom-Driven Imaging: Reserve follow-up neuroimaging for any new polyuria, headache, or visual symptoms.
3. Systemic Monitoring: Screen for secondary manifestations of IgG4-RD in other organ systems (e.g., retroperitoneum, pancreas, salivary glands) if systemic symptoms emerge.
Hello Attending Consultant here
Critique: Surveillance plan is sound but under-specifies relapse biomarkers and multi-organ screening intervals; over-relies on symptom-driven imaging when subclinical recurrence can precede CDI/headache. Endocrine recovery is excellent—document durability metrics.
Top 3 DDx:
1. Resolved IgG4-RD hypophysitis (biopsy + Rx confirmed)
2. Late IgG4-RD relapse (seronegative possible)
3. Secondary empty-sella/endocrine sequela
Specific points (6):
1. Annual serum IgG4 + free light chains + ESR/CRP even if initially normal.
2. Baseline PET-CT or CT CAP now if not done; q2–3 yr if high-risk phenotype.
3. Full pituitary panel (cortisol, TFT, gonadal, IGF-1, copeptin) at 6 mo then yearly.
4. MRI pituitary/sinus at 2 yr then prn; include DWI for early fibrosis.
5. Rheum/endo co-follow; educate on polyuria/diplopia red flags.
6. Bone health/DEXA post-steroids; no further B-cell depletion unless relapse.
7. Document CD19 recovery post-ritux for future dosing reference.
Hello, Expert Clinician here.
Final Unifying Diagnosis: Biopsy-proven IgG4-related hypophysitis and sphenoid sinusitis — now sealed by a therapeutic response: complete radiological resolution, reversal of CDI, and sustained drug-free remission at 4 years following rituximab and steroids.
Retrospective Lessons:
- The seronegative serum IgG4 and bystander MPO-ANCA nearly derailed the diagnosis — tissue biopsy was the decisive act.
- The reversible CDI is remarkable: infundibular IgG4-RD caught early remains functionally salvageable, unlike chronic fibrotic disease where stalk deficits are typically permanent.
- Rituximab's success validates B-cell depletion as disease-modifying, not merely steroid-sparing.
Key Pivot: The commitment to biopsy before empiric immunosuppression — every non-invasive test was equivocal; only histopathology and subsequent therapeutic response confirmed truth.
Current Priority: Structured relapse surveillance — annual serum IgG4, full pituitary panel, and symptom-triggered imaging — since seronegative relapses occur in ~30% of IgG4-RD.
Teaching Pearl: This case is the archetype of "diagnose by tissue, confirm by response" — in skull-base infiltrative disease with normal serology, biopsy is not the last resort; it is the first correct answer, and early rituximab can reverse what was once considered irreversible pituitary dysfunction.